United Therapeutics (UTHR) Tops Q2 EPS Expectations
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
United Therapeutics (UTHR) PT, Estimate Raised at BMO Capital
July 29, 2014 3:44 PM EDTBMO Capital analyst Jim Birchenough reiterated an Outperform rating and boosted his price target on United Therapeutics Corp. (NASDAQ: UTHR) to $165.00 (from $150.00) following strong Q2 results.
"We maintain our Outperform rating on shares of UTHR following review of 2Q14 results. With above-consensus... More
